Agency for Health Technology Assessment and Tariff System

What Agency for Health Technology Assessment and Tariff System does

Agencja Oceny Technologii Medycznych i Taryfikacji (AOTMiT), branded in English as the Agency for Health Technology Assessment and Tariff System, is a Polish state agency headquartered in Warsaw at ul. Przeskok 2, established under the Act of 27 August 2004 on healthcare services financed from public funds and operating under the supervision of the Ministry of Health. It is the sole statutory body in Poland responsible for health technology assessment (HTA) of medicinal products, medical devices, and healthcare services, for setting tariffs for publicly funded healthcare services, and for issuing opinions and recommendations on health policy programs (PPZ) implemented by local government units. Its outputs feed directly into reimbursement and pricing decisions made by the Ministry of Health and implemented by the National Health Fund (NFZ), making AOTMiT a critical gatekeeper for the Polish public reimbursement system.

The agency's core products include the HTA and tariff-setting services (Taryfikacja), verification analyses (Analiza Weryfikacyjna, AWA) submitted by marketing authorization holders in reimbursement proceedings, the free web-based SRK (Standard Rachunku Kosztów, Cost Accounting Standard) Application at appsrk.aotm.gov.pl, the SOLR reimbursement-list handling system, the Biblioteka AOTMiT knowledge library, Collegium AOTMiT training programs, and the clinical recommendations toolkit built on AGREE II, ADAPTE, and GRADE methodologies. The technology backbone is a government health technology assessment and tariff-setting platform with two specialized assessment departments (drug and non-drug technology), supporting infrastructure for cost data collection from healthcare providers, and public-facing portals including a multi-language website, Public Information Bulletin (BIP), and active social media presence on Twitter/X, LinkedIn, and YouTube.

AOTMiT's revenue is primarily state budget allocation from the Ministry of Health, supplemented by regulated verification analysis fees (PLN 140,364 per AWA since 4 May 2022, capped at PLN 150,000 by law) and EU project funding. It serves five distinct customer segments: pharmaceutical and medical device marketing authorization holders (primary revenue-bearing segment via AWA fees), healthcare service providers (Świadczeniodawcy) that use the SRK Application and engage in tariff consultations, local government units (JST) that receive opinions on health policy programs, healthcare professionals and clinical experts, and patients and patient organizations. The agency also operates as a regional HTA knowledge hub through its CEE Workshops and active participation in EU projects (EUnetHTA JA3, ICD-11, CAPRICORD, AUGMENT Biosimilars, EURIPID, Impact HTA, Kompas, Profibaza, SMoKL).

Name

Agency for Health Technology Assessment and Tariff System

Legal name

Agencja Oceny Technologii Medycznych i Taryfikacji

Website

https://aotm.gov.pl

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

101–250 employees

Short description

AOTMiT is the Polish state agency that conducts health technology assessments and sets tariffs for publicly funded healthcare, operating under the Ministry of Health. It serves pharmaceutical and medical device applicants, healthcare providers, local governments, and patients across Poland and EU HTA projects.

Ownership category

akta.pro rank

Product category

Health Technology Assessment Services

NAICS

Pharmacy Benefit Management and Other Third Party Administration of Insurance and Pension Funds (524292)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro industry

PRIMARYHLAJACAF

Health Technology Assessment (HTA) & Reimbursement Policy Bodies

Healthcare & Life Sciences/Public Health, Government & Regulators/Health Policy, Regulation & Compliance Authorities

Keywords

• Health technology assessment
• Tariff setting
• Medical reimbursement analysis
• Cost accounting standards
• Clinical recommendations

Headquarters

HQ city

Warszawa

HQ country

Poland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Others

Revenue model

1. Verification Analysis Fees (AWA): The Agency charges fees for preparing verification analyses (AWA) of medicinal products, foodstuffs for special nutritional purposes, and medical devices submitted in reimbursement proceedings. The fee since 4 May 2022 is PLN 140,364. The fee is paid to the Agency's bank account and cannot exceed PLN 150,000 per the Act of 12 May 2011 on reimbursement.
2. Government Budget Funding: As a Polish government agency, AOTMiT is funded through the state budget under the Ministry of Health. Operations include issuing opinions, conducting assessments, managing EU projects, and providing training through Collegium AOTMiT.

Pricing tiers

Distribution channels4 records

Marketing channels6 records

Core offering

AOTMiT is a Polish government agency that performs health technology assessments of medicinal products, medical devices, and healthcare procedures to support public reimbursement decisions. It also sets tariffs for publicly funded healthcare services, prepares Verification Analyses (AWA) for reimbursement proceedings, issues opinions and recommendations on Health Policy Programmes (PPZ) and clinical guidelines, and operates the free SRK Application for cost accounting and benchmarking across healthcare providers.

Product overview

AOTMiT (Agency for Health Technology Assessment and Tariff System) is a Polish government agency that provides health technology assessment and tariff system services. The core offerings include HTA services for assessing medicinal products and medical devices, a tariff system for healthcare services, and the SRK Application (Cost Accounting Standard Application). Supporting services include Health Policy Programme recommendations, Clinical Recommendations tools (AGREE II, ADAPTE, GRADE), Collegium AOTMiT training programmes, and the AOTMiT Library. The SOLR system handles reimbursement list processing.

Differentiator

Problem solved

Functional benefit

Products and services

• Health Technology Assessment (HTA) Services Assessment of medicinal products, medical devices, and diagnostic/therapeutic procedures to determine eligibility for inclusion in Poland's public reimbursement system. Outputs feed into Ministry of Health and National Health Fund (NFZ) decisions.
• Tariff System (Taryfikacja) Methodology and data acquisition for setting tariffs for publicly funded healthcare services, including publication of tariff reports and management of tariff proceedings.
• Verification Analysis (AWA) Analysis of clinical, economic, and budget impact submitted by marketing authorization holders as part of the Polish reimbursement process. Fee regulated by law (max PLN 150,000 per Act on Reimbursement).
• Health Policy Programmes (PPZ) Opinions and Recommendations Opinions, recommendations, and instructions for local government units (JST) planning, implementing, and evaluating public health policy programs. Includes the PPZ Wizard tool.
• Aplikacja SRK (Standard Rachunku Kosztów / Cost Accounting Standard Application) Free, innovative tool enabling cost settlement, procedure valuation, benchmarking, and effective management for healthcare service providers implementing the Cost Accounting Standard.
• Collegium AOTMiT Training Programmes Structured training programmes organized by AOTMiT for healthcare professionals covering cost accounting standards, health technology assessment, and health policy programmes. Includes webinars, presentations, document templates, and FAQs.
• Clinical Recommendations (Zalecenia Kliniczne) Development, adaptation, and opinion of clinical recommendations using AGREE II, ADAPTE, GRADE, and GIN-McMaster methodologies for the Polish healthcare context.
• Biblioteka AOTMiT (AOTMiT Library) Compendium of knowledge on good practices in health technology assessment and evidence-based medicine, available to clinicians and researchers.

Quantifiable outcome

• The agency has been operating for 20 years as one of the strongest and most recognized HTA institutions in Europe
• +2 more outcomes

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered core, major and minor.

• Ministry of Health of Poland (Ministerstwo Zdrowia)coreOthersThe Ministry of Health is the supervisory body of AOTMiT and issues binding orders (zlecenia MZ) for health technology assessments. AOTMiT provides verification analyses, opinions, and recommendations that feed into the Ministry's reimbursement and pricing decisions.
• National Health Fund (Narodowy Fundusz Zdrowia, NFZ)coreStrategic or Co-development PartnerNFZ is Poland's public health insurer and the primary payer implementing reimbursement decisions. AOTMiT cooperates with NFZ on tariff setting for healthcare services and reimbursement implementation based on HTA assessments.
• European Commission / EU Funding BodiesmajorStrategic or Co-development PartnerAOTMiT participates in multiple EU-funded projects including ICD-11, CAPRICORD, AUGMENT Biosimilars, EURIPID, EUnetHTA JA3, Impact HTA, Kompas, Profibaza, and SMoKL (Treatment Cost Monitoring System). These projects enhance the agency's methodological capabilities and contribute to European health technology assessment harmonization.
• EUnetHTA (European Network for Health Technology Assessment)majorStrategic or Co-development PartnerActive participation in EUnetHTA JA3 (Joint Action 3), contributing to and benefiting from European-level HTA collaboration, methodological harmonization, and joint assessment frameworks across EU member states.
• CAPRICORD Project PartnersminorStrategic or Co-development PartnerCAPRICORD is a project involving collaboration with patient organizations to improve patient access to modern, effective, and safe biological therapies. AOTMiT actively engages in activities to enhance biosimilar adoption.
• AUGMENT Biosimilars Project ConsortiumminorStrategic or Co-development PartnerAUGMENT Biosimilars is an EU project focused on building capacity for biosimilar medicines in Europe, in which AOTMiT participates to improve patient access to biological therapies.
• Central and Eastern European (CEE) Countries HTA NetworkminorStrategic or Co-development PartnerAOTMiT organizes CEE Workshops for health technology assessment, building regional capacity and sharing knowledge with Central and Eastern European countries on HTA methodologies and practices.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Haute Autorité de Santé (HAS): HAS is France's independent public authority that assesses health technologies, issues clinical guidelines, and evaluates healthcare facilities. Its mandate covering HTA, guidelines, and accreditation closely parallels AOTMiT's combined HTA, tariff, and clinical recommendations remit.
• Zorginstituut Nederland (ZIN): ZIN is the Netherlands' national HTA body that advises on the basic health insurance package and manages reimbursement decisions. Like AOTMiT, it is a statutory agency producing assessments that feed into binding reimbursement and pricing decisions.
• Institute for Quality and Efficiency in Health Care (IQWiG): IQWiG is Germany's independent HTA agency that produces benefit assessments for the German Federal Joint Committee (G-BA). It performs clinical and economic evaluations for reimbursement decisions in a single-payer system, mirroring AOTMiT's role in Poland's NFZ-funded system.
• Austrian Institute for Health Technology Assessment (AIHTA): AIHTA is part of the Austrian National Public Health Institute and produces HTA reports for Austrian reimbursement decisions. It is a smaller, methodology-focused peer with similar remit to AOTMiT's HTA Department.
• Belgian Health Care Knowledge Centre (KCE): KCE is Belgium's federal HTA agency producing scientific analyses to inform health policy, reimbursement, and clinical practice. It functions as an evidence-generating arm of the Belgian state analogous to AOTMiT's role for Poland.
• National Institute for Health and Care Excellence (NICE): NICE is the United Kingdom's statutory HTA body that issues technology appraisal guidance and clinical guidelines used by the NHS. Like AOTMiT, it conducts reimbursement-relevant assessments, sets standards, and provides national-level health technology recommendations, making it the most structurally comparable peer.
• Norwegian Institute of Public Health (NIPH) - Health Technology Assessment division: NIPH hosts Norway's national HTA function (including the former NOKC) and conducts systematic reviews and HTA reports for Norwegian reimbursement and clinical guideline decisions. It is a comparably sized public-sector HTA producer with a similar methodology-driven remit.
• Dental and Pharmaceutical Benefits Agency (TLV), Sweden: TLV is Sweden's central government agency that decides which pharmaceuticals, dental care, and medical devices are subsidized. It combines reimbursement decision-making with health-economic pricing analysis, directly comparable to AOTMiT's HTA-plus-tariff dual mandate.

Regional players

• Healthcare Improvement Scotland: Healthcare Improvement Scotland includes the Scottish Health Technologies Group, which conducts HTA for NHS Scotland. It shares AOTMiT's evidence-based assessment and clinical guideline functions but operates in a distinct, smaller national jurisdiction.

Others

• State Institute for Drug Control (SÚKL), Czech Republic:

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/aotmit
• YouTubeyoutube.com/channel/UC0iRJZwpp66TUlhPgqX8y3g
• LinkedInlinkedin.com/company/agencja-oceny-technologii-medycznych-i-taryfikacji
• Facebookfacebook.com/AOTMiT

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Agency for Health Technology Assessment and Tariff System